We are the first publicly traded company to leverage Canton Coin (“CC”) and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. In addition to driving value through activities on the Canton Network, we also operate clinical-stage biotech research and development programs.
Stage not disclosed · ActiveModality: buccal film (small molecule)
Aliases TH104
Target Opioid receptors (mu-opioid antagonist)
Indications
Prophylactic protection against synthetic opioid exposure(Stage not disclosed)
Catalysts
— H1 2027
— H1 2028
Status note Proprietary buccal film of nalmefene 16 mg for military and first-responder populations. Type C meeting with FDA in March 2025 confirmed no additional clinical trials required to support NDA submission. Company undertook a November 2025 strategic shift prioritizing a digital asset treasury strategy, but the therapeutic pipeline (via subsidiary Gravitas) remains active.
Partnerships Intract Pharma: exclusively licensed global development/commercialization rights (outside South Korea) to Soteria and Phloral oral delivery platforms plus infliximab supply
Indications
Immunology/inflammation (specific indication not stated)(Stage not disclosed)
Status note Oral formulation of infliximab (chimeric anti-TNF-alpha mAb) aimed at eliminating infusion burden.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.